Supect (Radotinib) CML Chronic Myeloid Leukemia
|
The drug called Supect and made from radotinib (IY5511) by Il-Yang Pharmaceutical Co. in South Korea is the first anti-leukemia drug made in Asia.
This drug can also be administered to people who are non-responsive or resistant to current drugs as imatinib, nilotinib and dasatinib. ''A research team at Seoul St. Mary's Hospital's hematopoetic stem cell transplant center, led by professor Kim Dong-Wook, administered the new medicine, named IY5511, to 22 chronic myeloid leukemia patients from July 2008''... Extract from Youhp |
|
Korean Pharmaceutical Company Develops New Leukemia Treatment
January 6, 2012, Arirang
Sale of new drug for myelogenous leukemia approved
January 5, 2012, Korea Times
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, OANA News
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, Yonhap News Agency
Radotinib approved in South Korea for CML
January 5, 2012, Biotech strategy blog
New S. Korean Leukemia Drug Begins Final Phase of Clinical Trials
August 12, 2011, KBS World
New Leukemia Drug Shows Promise
July 30, 2009, Korea Times
New Leukemia Drug developed by Korean Drug Maker
July 29, 2009, MySpace.com
January 6, 2012, Arirang
Sale of new drug for myelogenous leukemia approved
January 5, 2012, Korea Times
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, OANA News
S. Korea approves Asia's first anti-leukemia drug
January 5, 2012, Yonhap News Agency
Radotinib approved in South Korea for CML
January 5, 2012, Biotech strategy blog
New S. Korean Leukemia Drug Begins Final Phase of Clinical Trials
August 12, 2011, KBS World
New Leukemia Drug Shows Promise
July 30, 2009, Korea Times
New Leukemia Drug developed by Korean Drug Maker
July 29, 2009, MySpace.com
Clinical Trial Centers
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase
Patients
'